Israeli clinical-stage immunotherapy developer Enlivex Therapeutics Ltd. (NASDAQ: ENLV), on Monday reported positive six-month efficacy results from the Phase IIa segment of its multi-country Phase I/II Allocetra trial in moderate to severe knee osteoarthritis.

Enlivex reported that Allocetra delivered substantial and durable reductions in pain and improvements in function for patients aged 60 and above, with outcomes consistent with earlier three-month findings which previously observed positive correlations between age and clinical effect.

According to the data, a composite pain-and-function endpoint achieved statistical significance at three months in patients aged 60 and above and again at six months in patients aged 61 and above, showing marked improvement compared with placebo.

The therapy also maintained a favourable safety profile in line with earlier observations.

Management said the results support the therapeutic potential of a single treatment cycle lasting at least six months and described the findings as a strong foundation for commercial development.

Enlivex plans to start a Phase IIb study of Allocetra in age-related primary knee osteoarthritis in the first half of 2026.